
BiomX Inc. (PHGE) Stock Forecast & Price Target
BiomX Inc. (PHGE) Analyst Ratings
Bulls say
BiomX Inc. demonstrates a strong positive outlook due to favorable clinical trends evidenced by its BX211 candidate, which shows improvement in key parameters such as infection resolution and reductions in C-Reactive Protein levels among patients with diabetic foot osteomyelitis. The company's recent advancements, including FDA support for its BX011 multi-phage cocktail moving into Phase 2a trials, further bolster its prospects, as these trials target multiple efficacy endpoints and aim to enhance lung function and quality of life for cystic fibrosis patients. Additionally, BiomX's strategic plans for market penetration, expansion of indications based on clinical data, and broader valuations that include ex-U.S. markets suggest significant commercial potential and a clear regulatory trajectory moving forward.
Bears say
BiomX Inc. is experiencing negative investor sentiment due to the marginal results from its clinical trials, specifically the p-values for key endpoints which narrowly missed conventional thresholds for statistical significance. The company's potential for future growth is further constrained by risks associated with failed or inconclusive clinical trials, challenges in securing adequate funding for drug development, and the threat of dilutive capital raises impacting shareholder value. Additionally, the lack of commercial success in delivering effective treatments adds to the negative outlook for BiomX's stock performance.
This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.
BiomX Inc. (PHGE) Analyst Forecast & Price Prediction
Start investing in BiomX Inc. (PHGE)
Order type
Buy in
Order amount
Est. shares
0 shares